

- A**
- Absolute lymphocyte count, 122, 459, 510
  - ACVBP regimen, 458, 478
  - Adjuvant therapy, 422
  - Adolescents, 92, 97, 271, 272, 278, 280, 293, 348
  - Adult T-cell leukemia, 267, 474
  - Adult T-cell lymphoma, 243, 372
  - Aggressive lymphoma, 25, 30, 48, 71, 82, 85, 92, 144, 152, 155, 222, 258, 322, 325, 329, 334, 368, 397, 451, 460, 480, 484, 503
  - AIDS, 341, 397, 488, 489, 493
  - Alemtuzumab, 123, 261, 266, 476
  - ALK, expression, 127
  - ALK, gene, 270
  - Alkylating agents, 39, 42, 126, 134, 275, 319, 354, 355, 362, 400, 486
  - Allogeneic hematopoietic stem cell transplantation, 501
  - Allogeneic stem cell transplantation, 39, 40, 123, 246, 339, 479
  - Allogeneic transplantation, 5, 76, 289, 457, 481
  - Allogenic transplantation, 37
  - Allopurinol, 280, 306
  - Anaplastic large cell lymphoma, 40, 94, 100, 171bis, 229, 242, 248, 272, 276, 323, 368, 387, 408, 409, 490
  - Anaplastic lymphoma kinase, 93, 94
  - Anemia, 24, 112, 134, 144, 152, 160, 235, 249, 261, 266, 308, 309, 314, 331, 341, 354, 355, 359, 408, 434, 436, 465, 467, 507, 512, 513
  - Angiogenesis, 174, 204, 388
  - Angioimmunoblastic T-cell lymphoma, 128, 214, 229, 242, 246, 471
  - Animal models, 2, 96, 118, 132, 133, 156, 172, 175, 177, 178, 180, 184, 248, 290, 347, 349, 357, 376, 388, 501, 502
  - Anthracycline, 101, 105, 147, 150, 155, 316, 324, 434, 455, 461
  - Anthracyclines, 101, 105, 127, 147, 150, 155, 316, 324, 434, 455, 461
  - Antiangiogenic therapy, 249, 472
  - Antibody response, 94
  - Anti-CD20 antibody, 66, 109, 144, 209, 314, 349, 478
  - Anti-CD20 monoclonal antibody, 6, 143, 505
  - Anti-CD30 antibody, 125, 160
  - Antiretroviral therapy, 488, 489, 490, 493
  - Anti-tumor immunity, 399
  - Anxiety, 19, 511
  - Apoptosis, 14, 57, 59, 63, 115, 125, 130, 132, 133, 146, 152, 154, 156, 160, 174, 178, 180, 186, 199, 245, 249, 348, 350, 351, 352, 353, 356, 357, 385, 387, 390, 398, 399, 409, 437, 501, 502, 503
  - Apoptosis, chemotherapy-induced, 180
  - Arsenic trioxide, 238
  - Ascorbic acid, 238
  - ASCT, 23, 33, 36, 72, 73, 75, 76, 100, 101, 102, 103, 127, 128, 140, 145, 152, 161, 164, 182, 219, 232, 235, 248, 250, 252, 253, 254, 255, 256, 258, 259, 288, 315, 316, 330, 345, 430, 464, 476, 479, 486, 498, 500
  - Autoantibodies, 94, 397
  - Autologous bone marrow transplantation, 362
  - Autologous stem cell transplantation, 36, 75, 76, 101, 102, 108, 121, 182, 246, 248, 251, 254, 257, 259, 277, 289, 316, 498
  - Autologous transplantation, 3, 18, 33, 36, 37, 39, 41, 62, 73, 75, 76, 98, 99, 101, 102, 108, 109, 121, 125, 127, 145, 160, 176, 182, 212, 219, 221, 230, 232, 246, 248, 251, 252, 254, 257, 259, 277, 284, 288, 289, 291, 316, 362, 435, 436, 446, 457, 473, 474, 475, 476, 478, 480, 481, 496, 498
  - Autopsy, 486
- AZD1480**, 353
- B**
- B symptoms, 17, 26, 107, 128, 242, 245, 250, 288, 291, 334, 368, 400, 407, 408, 427, 430, 432, 441, 448, 496
  - b<sub>2</sub>-M, 510
  - B-ALL, 91, 281, 338, 348
  - Bax, 133, 387, 410, 412
  - B-cell clonality, 471
  - B-cell differentiation, 56, 390
  - B-cell lymphoma, 71, 73, 81, 82, 95, 138, 151, 175, 195, 196, 197, 198, 199, 252, 254, 258, 282, 298, 322, 325, 327, 329, 333, 339, 373, 413, 474, 484
  - B-cell malignancies, 158, 268, 505, 507
  - B-cell type, 51
  - Bcl-2, 80, 130, 132, 133, 155, 195, 303, 405, 410, 412, 440, 448
  - BCL-6, 86, 184, 390, 405, 472
  - B-CLL, 509
  - BCNU, 33, 475
  - BEACOPP regimen, 45, 163, 166, 227, 285, 494, 497, 499, 500
  - BEAM regimen, 486
  - Bendamustine, 42, 67, 126, 158, 231, 236, 255, 266, 288, 299, 305, 309, 319, 349, 389, 428, 507
  - Binet stage A, 260, 264, 510
  - Bispecific molecule, 65
  - Bleomycin, 30, 283, 286, 290, 341, 418, 497
  - Blood–brain barrier, 36
  - Bone disease, 43
  - Bone marrow, 5, 14, 18, 26, 27, 32, 41, 43, 48, 84, 91, 96, 113, 114, 115, 118, 183, 186, 190, 216, 246, 257, 264, 271, 272, 273, 275, 276, 280, 288, 303, 325, 327, 336, 357, 374, 377, 400, 406, 413, 417, 419, 424, 427, 430, 432, 433, 437, 441, 444, 448, 451, 456, 464, 474, 477, 484, 492, 493, 502, 510, 515
  - Bone marrow, biopsy, 26, 43, 417
  - Bone marrow, involvement, 18, 43, 48, 84, 91, 246, 276, 280, 288, 325, 419, 424, 430, 433, 437, 448, 456, 477
  - Bone marrow, transplantation, 5
  - Borrelia burgdorferi, 296
  - Bortezomib, 3, 109, 116, 117, 130, 146, 164, 237, 307, 308, 310, 319, 354, 355, 356, 357, 436, 437, 452
  - Brain natriuretic peptide, 455
  - Breast cancer, 149
  - Breast implants, 171bis
  - Burkitt lymphoma, 170bis
- C**
- CAL-101, 350, 351, 352
  - CAMPATH-1H, 39
  - Camptothecins, 348
  - Canada, 216
  - CAP, 155, 452
  - Carboplatin, 140, 486
  - Cardiac toxicity, 126, 343, 345, 491
  - Carfilzomib, 117, 354, 355, 357, 502
  - Case–control study, 168, 170
  - Caspase 3, 146, 410, 412
  - Caspase 3, expression, 410, 412
  - CD3, 68, 77, 171, 214, 245, 346, 347, 374, 407, 472
  - CD5<sup>+</sup>, 190, 210, 432, 436
  - CD10 expression, 214
  - CD15, 104, 150, 203, 409, 484, 485
  - CD20, 6, 17, 21, 61, 65, 66, 104, 110, 136, 142, 143, 144, 150, 158, 171, 203, 205, 206, 245, 254, 261, 264, 278, 282, 303, 309, 319, 327, 329, 347, 348, 349, 374, 389, 399, 413, 432, 445, 457, 471, 472, 479, 483, 505, 506
  - CD20 antigen, 413
  - CD20 expression, 205, 327, 348, 505
  - CD20<sup>+</sup>, 17, 66, 104, 136, 144, 150, 203, 205, 245, 254, 264, 309, 329, 348, 389, 413, 432, 457, 472
  - CD20<sup>+</sup> cells, 205, 389
  - CD23, 83, 374, 432, 472
  - CD30, 104, 125, 150, 160, 203, 270, 324, 387, 409, 440, 472, 473, 484, 485, 504
  - CD30 expression, 160
  - CD34<sup>+</sup> cells, 172, 212, 254, 374, 434, 435, 476, 477, 478
  - CD38, 83, 260, 263, 373, 374, 510
  - CD40, 67, 145, 376, 387
  - CD80, 376
  - 2CdA, 124, 134, 269
  - CEA, 429, 468, 497
  - Cell cultures, 374
  - Cell cycle, 57, 59, 115, 133, 154, 179, 199, 234, 353, 356, 357, 384, 393
  - Cell lines, 56, 57, 58, 59, 60, 118, 131, 133, 146, 151, 154, 155, 156, 157, 161, 174, 175, 180, 184, 186, 187, 188, 189, 193, 201, 202, 255, 348, 350, 351, 353, 356, 373, 376, 379, 381, 384, 385, 387, 501, 502, 503, 506
  - Central nervous system, 28, 31, 32, 33, 34, 36, 54, 68, 71, 79, 88, 89, 91, 210, 258, 271, 272, 274, 276, 278, 279, 280, 333, 339, 340, 342, 371, 380, 390, 453, 456, 464, 465, 466, 484, 485, 488, 490, 492
  - CGH, 55, 58, 95, 186, 191, 244, 268, 376
  - Chemoimmunotherapy, 4, 265, 400, 429
  - Chemokine, 11, 14, 64, 161, 353
  - Chemoradiotherapy, 420, 462
  - Chemoresistance, 132, 332
  - Chemosensitivity, 76, 219
  - Chemotherapy, 4, 5, 7, 14, 18, 20, 21, 22, 24, 25, 26, 31, 33, 36, 38, 44, 45, 48, 49, 64, 66, 69, 71, 72, 74, 75, 76, 81, 88, 90, 91, 99, 100, 101, 103, 105, 107, 108, 110, 111, 113, 121, 123, 131, 132, 134, 135, 136, 137, 139, 140, 141, 144, 147, 148, 149, 155, 162, 166, 167, 172, 173, 180, 185, 207, 209, 215, 217, 219, 220, 221, 222, 224, 229, 231, 232, 234, 235, 239, 245, 248, 249, 250, 251, 252, 253, 256, 257, 258, 259, 271, 272, 273, 274, 277, 278, 279, 280, 281, 282, 286, 287, 291, 293, 294, 299, 304, 305, 307, 309, 312, 313, 315, 316, 317, 318, 320, 321, 322, 323, 324, 325, 326, 329, 330, 332, 334, 337, 338, 339, 340, 342, 344, 345, 349, 356, 361, 362, 365, 369, 385, 388, 389, 405, 408, 418, 420, 421, 424, 426, 427, 428, 429, 431, 432, 434, 443, 445, 447, 448, 450, 451, 453, 455, 459, 460, 461, 463, 464, 465, 466, 468, 470, 471, 473, 475, 477, 482, 483, 484, 486, 488, 489, 490, 491, 493, 494, 496, 497, 498, 499, 500, 505
  - Chemotherapy-induced apoptosis, 180
  - Childhood lymphoma, 273
  - Chlorambucil, 20, 114, 120, 134, 136, 238, 295, 304, 349, 418, 485
  - CHOP regimen, 4, 7, 16, 17, 22, 23, 28, 29, 30, 44, 48, 71, 74, 76, 78, 80, 86, 92, 101, 105, 110, 111, 128, 131, 135, 140, 145, 147, 148, 149, 194, 195, 209, 211, 212, 213, 215, 217, 218, 219, 220, 221, 222, 229, 232, 233, 234, 239, 240, 245, 248, 249, 256, 258, 291, 313, 320, 322, 323, 324, 328, 329, 333, 334, 336, 337, 338, 343, 345, 360, 361, 389, 407, 414, 427, 432, 433, 435, 440, 445, 448, 450, 452, 454, 456, 458, 459, 460, 461, 462, 465, 467, 471, 476, 483, 484, 489, 490, 505
  - CHOP therapy, 195, 336, 414, 467
  - Chromosomal abnormalities, 114, 195, 251, 262, 268, 420

- Chromosomal translocation, 1, 55, 81, 133, 192, 356, 398
- Chromosomal, aberrations, 55, 95, 97, 210
- Chromosomal, abnormalities, 114, 251, 268, 420
- Chromosomal, instability, 376
- Chromosomal, translocations, 1, 55, 81
- Chronic lymphocytic leukemia, 61, 83, 87, 114, 153, 158, 176, 208, 261, 352, 362, 377, 388, 392, 454, 513
- Cisplatin, 101, 111, 434
- Cladribine, 14, 124, 269, 362
- Clinical guidelines, 511
- Clinical trials, 3, 44, 66, 105, 124, 127, 139, 144, 146, 151, 155, 216, 243, 269, 289, 326, 332, 335, 349, 417, 430, 431, 451, 465, 472, 476, 478, 496, 504, 506
- Clinical trials, design, 3, 424
- Clinical, outcome, 13, 15, 19, 48, 62, 105, 119, 147, 154, 167, 173, 174, 176, 180, 181, 195, 202, 209, 222, 232, 243, 271, 324, 356, 379, 392, 399, 432, 433
- Clinical, stage, 48, 222, 227, 232, 248, 282, 293, 345, 365, 409, 471, 498
- Clinicopathological, features, 150, 282, 368
- Colon cancer, 294
- Colorectal cancer, 294
- Combination chemotherapy, 4, 7, 151, 294, 405, 444
- Combination treatment, 2, 4, 7, 14, 57, 62, 64, 66, 74, 82, 86, 93, 109, 110, 111, 131, 133, 136, 137, 141, 144, 145, 146, 149, 151, 153, 158, 179, 206, 209, 212, 236, 238, 239, 249, 252, 266, 280, 294, 295, 299, 301, 304, 306, 309, 311, 319, 327, 328, 329, 339, 341, 349, 350, 351, 353, 357, 362, 365, 405, 410, 434, 435, 437, 444, 450, 457, 461, 470, 476, 477, 482, 488, 491, 499, 502, 505, 507, 512
- Combined modality therapy, 26, 250, 283, 455
- Combined therapy, 327
- Complete response, 3, 20, 22, 25, 31, 34, 37, 41, 69, 74, 107, 110, 113, 120, 136, 137, 153, 203, 215, 218, 219, 226, 234, 236, 240, 247, 252, 300, 304, 306, 311, 313, 327, 360, 407, 428, 437, 438, 464, 470, 484, 485, 488, 495, 505
- Computed tomography, 4, 26, 28, 43, 45, 46, 47, 48, 53, 63, 105, 107, 110, 145, 147, 148, 149, 161, 162, 163, 182, 217, 220, 222, 223, 224, 225, 228, 229, 232, 248, 249, 255, 272, 273, 275, 279, 283, 284, 286, 294, 300, 313, 339, 341, 362, 369, 394, 413, 414, 415, 417, 419, 420, 422, 446, 464, 476, 477, 483, 491, 496, 502
- Concurrent therapy, 81, 325, 372, 405
- Conventional chemotherapy, 73, 99, 100, 128, 284, 434, 446, 461, 479, 490, 507
- Cost-effectiveness, 6, 429
- Cutaneous T-cell lymphoma, 40, 247, 507
- CVP regimen, 458
- Cyclin dependant kinases, 357
- Cyclin, D1, 15, 17, 59, 210, 351, 436
- Cyclin, dependent kinase, 357
- Cyclophosphamide, 16, 30, 40, 42, 72, 73, 88, 98, 101, 106, 116, 120, 121, 123, 195, 221, 259, 275, 280, 283, 319, 328, 337, 341, 342, 343, 361, 385, 435, 456, 463, 467, 479, 486, 488, 491, 513
- Cytarabine, 23, 30, 33, 34, 54, 72, 75, 111, 112, 234, 236, 239, 255, 258, 278, 279, 380, 453, 463, 475, 477, 492, 498
- Cytogenetic, 51, 55, 83, 85, 114, 117, 201, 210, 262, 263, 267, 268, 271, 376, 392, 419, 509, 510
- Cytogenetic, aberrations, 271
- Cytogenetic, abnormalities, 114, 117, 262, 271, 419
- Cytogenetic, analysis, 55, 271
- Cytogenetic, features, 117, 210
- Cytogenetic, 12, 118, 155, 159, 161, 174, 301, 311, 377
- Cytomorphology, 31
- Cytotoxic T-cells (CTL), 68, 388, 484
- Cytotoxic therapy, 21
- Cytotoxicity, 65, 156, 209, 212, 238, 306, 311, 346, 347, 348, 353, 502
- D**
- Dacarbazine, 497
- Death, 30, 42, 46, 56, 63, 65, 91, 107, 125, 132, 145, 149, 152, 156, 160, 203, 209, 256, 261, 265, 270, 271, 274, 277, 285, 286, 287, 292, 305, 316, 321, 326, 327, 328, 334, 338, 341, 345, 348, 349, 353, 360, 421, 422, 424, 431, 437, 463, 469, 477, 488, 496, 497, 506, 512
- Dendritic cells, 176, 205, 311, 376, 441
- Denmark, 85, 198
- DepoCyte, 453
- Depression, 19
- Developing countries, 370
- Dexamethasone, 72, 75, 117, 355, 463, 482
- DHAP regimen, 101, 463
- Diagnosis, of malignant lymphoma, 374
- Diagnostic, markers, 82
- Differentiation, 12, 52, 56, 78, 80, 104, 190, 195, 197, 199, 311, 390
- Diffuse large B-cell lymphoma, 27, 29, 51, 60, 67, 78, 81, 85, 93, 94, 131, 139, 143, 146, 147, 151, 154, 156, 170bis, 171, 182, 188, 195, 196, 207, 210, 221, 277, 296, 323, 328, 333, 334, 336, 337, 343, 367, 374, 381, 399, 405, 440, 447, 448, 450, 456, 459, 460, 462, 467, 474, 478, 483, 484
- Diffuse large cell lymphoma, 368, 458
- Disease progression, 47, 48, 69, 109, 122, 145, 153, 222, 225, 230, 238, 246, 254, 266, 306, 315, 334, 338, 342, 373, 420, 429, 431, 433, 436, 438, 439, 496, 507, 509, 510
- DNA, 9, 32, 55, 60, 96, 97, 115, 119, 132, 142, 159, 183, 186, 191, 192, 206, 245, 262, 269, 286, 296, 313, 363, 390, 392, 406, 468, 483, 495, 502, 503
- Dose dense chemotherapy, 90, 106
- Dose escalation, 29, 70, 110, 153, 266, 286, 314
- Dose intensification, 101
- Dose intensity, 285, 286, 332, 460, 499
- Doxorubicin, 30, 72, 73, 105, 106, 111, 195, 221, 274, 283, 286, 328, 337, 343, 344, 345, 361, 418, 455, 456, 467, 491, 497
- Drug delivery, 439
- Drug resistance, 186, 373, 385
- Drug-induced apoptosis, 14
- Durable remission, 39, 249, 451
- E**
- Echocardiogram, 455
- Education, 165
- Elderly, 16, 27, 104, 105, 106, 107, 108, 134, 171, 223, 233, 239, 245, 282, 309, 324, 328, 329, 331, 334, 335, 337, 430, 451, 459, 460, 461, 466
- Elderly patients, 16, 104, 105, 107, 108, 223, 239, 309, 328, 329, 334, 337, 459, 460, 461
- Enteropathy-associated T-cell lymphoma, 129, 240
- Epirubicin, 101, 105, 341
- EPOCH, 71, 140, 150, 332, 479, 488, 489
- Erythropoiesis, 24
- ESHAP, 111, 221, 323, 338, 435, 463, 500
- Estrogen, 168
- Etoposide, 34, 73, 75, 92, 101, 111, 140, 255, 258, 316, 373, 463, 475, 488, 491, 497, 498
- Event-free survival, 21, 29, 102, 219, 259, 301, 309, 329, 371, 440, 447, 481
- Expression profiles, 59, 131, 197, 393, 440
- Extranodal involvement, 28, 29, 30, 321, 329, 336, 410, 412, 450, 451, 492, 493, 499
- Extranodal lymphoma, 193, 334
- F**
- Familial predisposition, 116
- Family history, 363
- Fas, 178, 184, 501
- Fas-mediated apoptosis, 178
- FCR, 121, 264, 512, 513
- Fertility, 166, 500
- Field radiotherapy, 285, 327
- Filgrastim, 286, 290
- First relapse, 75, 108, 136, 426, 427
- First remission, 6, 16, 71, 100, 243, 250, 427
- First-line therapy, 73, 252, 254, 426, 495
- FISH, 71, 81, 82, 83, 84, 85, 95, 96, 114, 117, 119, 120, 121, 187, 191, 201, 244, 251, 262, 268, 271, 275, 374, 376, 398, 430, 440, 512
- FISH analysis, 71, 82, 85, 191, 271, 374
- Flavopiridol, 14
- Flow cytometry, 13, 77, 115, 143, 172, 214, 245, 264, 347, 348, 352, 353, 374, 392, 432, 444, 505, 511
- Fludarabine, 14, 39, 40, 42, 112, 113, 114, 116, 120, 121, 122, 123, 134, 135, 233, 239, 261, 266, 305, 349, 362, 389, 427, 428, 479, 480, 486, 513
- Folinic acid, 333
- Follicle center lymphoma, 84
- Follicular dendritic cells, 471
- Follicular lymphoma, 4, 5, 7, 9, 12, 19, 20, 21, 22, 27, 28, 46, 60, 61, 67, 77, 83, 86, 95, 98, 110, 126, 135, 137, 142, 153, 189, 190, 195, 216, 221, 259, 296, 303, 304, 306, 309, 311, 312, 313, 314, 317, 318, 323, 325, 333, 362, 367, 374, 379, 381, 398, 399, 422, 424, 426, 427, 429, 447, 468, 470, 474, 479, 481, 490, 505, 507
- Follicular lymphoma, advanced stage, 4
- France, 165, 234, 515
- Front-line therapy, 226, 264
- G**
- GA101, 66, 143, 144, 348, 349, 505, 506,
- Gastric cancer, 33, 168
- Gastric MALT lymphoma, 389
- Gastrointestinal tract, 32, 104, 368, 405
- G-CSF, 106, 157, 221, 239, 283, 286, 290, 377, 434, 477, 497, 499
- Gemcitabine, 111, 164, 249, 434, 457
- Gene expression, 11, 12, 15, 44, 51, 55, 56, 58, 78, 79, 95, 131, 150, 154, 177, 180, 184, 186, 187, 188, 190, 194, 197, 211, 213, 251, 290, 383, 440, 441, 506
- Gene rearrangements, 85, 97, 262, 385, 408
- Gene, alterations, 187
- Gene, amplification, 1, 381
- Gene, expression profiling, 11, 12, 44, 51, 58, 78, 95, 150, 154, 180, 186, 187, 188, 441
- Gene, rearrangement, 85, 97, 262, 385, 408
- Genetic polymorphism, 13, 159, 212, 495
- Genetic, analysis, 51
- Genetic, polymorphisms, 13, 159, 212
- Genomic, aberrations, 191
- Genomic, profiling, 51, 244
- Geographical occurrence, 196
- Germany, 36, 196, 353
- Germinal center, 1, 56, 78, 146, 171, 183, 188, 189, 379, 381, 440, 448
- GM-CSF, 311
- Graft-versus-host disease, 40
- Graft-versus-host-disease (GVHD), 38, 39, 479
- Growth factors, 137, 140, 335, 342, 488
- H**
- HAART therapy, 49, 342
- Hairy cell leukemia, 268, 269, 362
- Hairy cell, leukemia, 268, 269, 362
- HD9 trial, 45
- Heat shock proteins, 146, 296
- Helicobacter pylori, 295, 467
- Hematological, malignancies, 238, 347, 362, 377, 397
- Hematological, toxicity, 6, 110, 124, 266, 331, 332, 499
- Hematopoiesis, 118
- Hemoglobin, 26, 106, 114, 116, 134, 408, 427, 451
- Hemophagocytic syndrome, 473
- Hepatic toxicity, 320, 454
- Hepatitis C, 138, 320, 325, 454
- Hepatitis C virus, 138, 320, 325
- Hepatocellular carcinoma, 468

- Herpes virus, 318  
 Heterozygosity, 13, 183, 191, 306  
 High dose chemotherapy, 33, 182, 253, 257, 281, 339, 430, 435, 446, 465, 475, 482, 493  
 High risk patients, 102, 219, 243, 333, 411, 483  
 High tumor burden, 90, 137, 308, 310  
 High-dose chemotherapy, 33, 182, 253, 257, 281, 339, 430, 435, 446, 465, 475, 482, 493  
 High-dose cytarabine, 31, 258, 434, 435, 463  
 High-dose methotrexate, 31, 33, 36, 54, 88, 258, 323, 463, 484  
 High-dose therapy, 16, 73, 98, 101, 108, 127, 233, 239, 254, 316, 478  
 Histological, subtypes, 48, 168, 276, 368, 370, 487  
 Histological, transformation, 257  
 Histone deacetylase inhibitor, 161, 359, 508  
 HIV infection, 8, 167, 171, 490, 493  
 HLA antigens, 11, 37, 42, 177, 187, 194, 374, 388, 390, 479, 481  
 Hodgkin's lymphoma, 10, 47, 48, 59, 67, 107, 113, 140, 157, 159, 160, 161, 162, 163, 164, 165, 166, 169, 172, 187, 203, 225, 226, 227, 228, 250, 273, 281, 283, 284, 285, 287, 288, 290, 292, 293, 294, 319, 323, 334, 353, 368, 369, 370, 393, 394, 397, 410, 411, 412, 418, 460, 480, 481, 490, 494, 495, 496, 497, 499, 504, 507  
 Hypercalcemia, 109, 354  
 Hyperuricemia, 280  
 Hypoxia, 107
- I**
- Idarubicin, 435  
 Idiotype vaccine, 61  
 Ifosfamide, 30, 31, 75, 88, 101, 140, 258, 434, 477  
 Ig genes, 59  
 IgV genes, 61  
 IL-10, 159, 377  
 IL-2, 247, 301, 347, 377  
 Immune response, 51, 62, 141, 159, 172, 176, 181, 209, 377, 384, 388, 390, 407, 441  
 Immune surveillance, 2  
 Immune system, 5, 61, 276  
 Immunochemotherapy, 7, 20, 22, 26, 34, 46, 98, 102, 110, 138, 147, 213, 217, 223, 236, 239, 274, 279, 301, 312, 338, 427, 448, 450, 454, 505  
 Immunocompetent patients, 32, 258, 324  
 Immunocytochemistry, 43, 484, 485  
 Immunoglobulin genes, 87  
 Immunohistochemistry, 44, 56, 77, 81, 95, 131, 150, 171, 183, 185, 186, 207, 213, 384, 389, 405, 410, 412, 445  
 Immunophenotyping, 81, 171, 198, 213, 244, 251, 267, 324, 374, 409, 448  
 Immunostaining, 80, 185, 194, 205  
 Immunosuppression, 53, 54, 171, 177, 340, 485  
 Immunotherapy, 61, 86, 113, 137, 172, 209, 212, 274, 315, 373, 484, 490  
 Immunotherapy strategies, 209  
 Incidence trends, 8  
 India, 465  
 Indolent lymphoma, 136, 155, 305, 309, 362, 368, 388, 389, 454, 480  
 Indolent lymphoma, advanced, 136  
 Infection, 39, 42, 51, 61, 66, 74, 107, 111, 123, 124, 137, 138, 141, 144, 145, 167, 193, 196, 199, 237, 239, 256, 258, 261, 286, 288, 296, 297, 318, 320, 324, 325, 342, 372, 384, 389, 400, 434, 439, 454, 457, 467, 477, 479, 490, 497, 508  
 Infectious complications, 91, 318, 457  
 Inferior progression-free survival, 111  
 Influenza, 141  
 Informed consent, 20, 73, 215, 242, 248, 313, 325, 397  
 Intensified induction, 478  
 Interferon alfa, 5, 16, 20, 21, 136, 138, 185, 233, 315, 377, 383, 389, 484, 485, 486  
 Interleukin-1, 50, 159, 301, 353, 377  
 Interleukin-2, 57, 62, 247, 301, 347, 377, 399  
 Interleukin-4, 159, 377  
 Interleukin-6, 118, 377  
 Interleukin-10, 159, 377  
 International Prognostic Index, 17, 28, 29, 30, 43, 48, 63, 71, 74, 75, 78, 81, 86, 92, 100, 102, 110, 127, 129, 139, 149, 181, 182, 194, 215, 218, 219, 220, 222, 232, 243, 248, 253, 254, 256, 295, 301, 320, 321, 326, 329, 330, 331, 332, 333, 334, 338, 340, 343, 345, 400, 419, 420, 421, 424, 426, 430, 433, 441, 445, 448, 450, 453, 457, 458, 459, 461, 478, 489, 491, 492, 508  
 Intra-arterial chemotherapy, 36  
 Intrathecal chemotherapy, 31, 278, 339, 453, 465, 488, 492  
 Intrathecal methotrexate, 465, 488  
 Intratumoral chemotherapy, 161  
 Involved field radiotherapy, 149, 407, 499  
 IPI score, 43, 63, 71, 74, 86, 127, 149, 181, 194, 253, 256, 295, 332, 433, 441, 448, 459, 461, 508  
 Irinotecan, 373  
 Italy, 170, 196, 198, 199, 296, 325
- J**
- Japan, 41, 171, 210, 216, 282, 317, 420, 474  
 JC virus, 318
- K**
- KIT, 115, 146, 156, 262
- L**
- Large B-cell lymphoma, 210, 272, 489  
 Laser microdissection, 179  
 Late toxicity, 25, 277  
 Lenalidomide, 109, 110, 117, 137, 249, 298, 306, 331, 346, 357, 436, 438, 439, 507  
 Leukemia, 14, 40, 97, 98, 119, 123, 143, 149, 177, 238, 240, 260, 262, 263, 267, 268, 271, 274, 317, 348, 362, 372, 385, 392, 408, 444, 480, 497, 501, 511  
 Leukemia, acute lymphoblastic, 91, 279, 348, 444  
 Leukemia, acute myeloid, 12, 27, 98, 149, 239, 281, 287, 314, 317, 362, 397  
 Leukemia, acute promyelocytic, 238  
 Leukemia, chronic lymphocytic, 12, 14, 15, 42, 61, 83, 87, 112, 114, 119, 120, 121, 122, 123, 126, 137, 143, 153, 158, 176, 177, 200, 203, 208, 260, 261, 262, 263, 264, 265, 266, 305, 327, 335, 352, 356, 362, 377, 381, 388, 392, 394, 397, 428, 454, 480, 481, 509, 510, 511, 512, 513  
 Leukemia, chronic myelogenous, 397  
 Leukoencephalopathy, 33  
 Leukopenia, 69, 152, 286, 436  
 Liposomal doxorubicin, 3, 345  
 Liver cirrhosis, 468  
 Long-term follow-up, 21, 250, 354, 359, 446, 491  
 Long-term survival, 18, 74, 250  
 Long-term toxicity, 149, 329  
 Lucatumumab, 67  
 Lung cancer, non-small-cell, 93  
 Lung cancer, small-cell, 93  
 Lymph nodes, 129, 178, 190, 234, 276, 376, 412, 413, 414, 441, 464, 515  
 Lymphoblastic lymphoma, 40, 272, 348, 372, 453, 474  
 Lymphoid malignancies, 289, 397, 480, 507  
 Lymphoma diagnosis, 325, 408, 487  
 Lymphoma subgroup, 471  
 Lymphoma transformation, 260  
 Lymphoma, aggressive, 25, 30, 48, 71, 82, 85, 92, 144, 152, 155, 222, 258, 322, 325, 329, 334, 368, 397, 451, 460, 480, 484, 503  
 Lymphoma, childhood, 273  
 Lymphomagenesis, 1, 2, 11, 60, 159, 168, 179, 180, 198, 398  
 Lymphomatous meningitis, 492  
 Lymphopenia, 69, 109, 245, 275, 306, 354, 355
- Lymphoplasmacytic lymphoma, 134, 190  
 Lymphoproliferative disorders, 268, 481, 484
- M**
- Mabthera, 136, 513  
 Magnetic resonance imaging, 34, 344, 456  
 Malignant lymphoma, 55, 193, 231, 321, 362, 368, 441, 446, 451, 456, 457, 459, 479  
 MALT, 67, 83, 153, 190, 192, 193, 275, 295, 296, 298, 299, 325, 367, 368, 389, 397, 405, 419, 420, 421, 462  
 MALT lymphoma, 192, 193, 275, 295, 296, 298, 299, 405, 419, 420  
 Mantle cell lymphoma, 15, 16, 18, 20, 39, 62, 67, 102, 109, 133, 143, 144, 153, 179, 180, 189, 230, 231, 234, 236, 238, 303, 309, 314, 325, 350, 351, 357, 374, 377, 381, 417, 428, 430, 431, 435, 437, 474, 479, 503  
 Marginal zone B-cell lymphoma, 170, 191, 192  
 Marginal zone lymphoma, 83, 137, 153, 190, 259, 275, 314, 377, 398, 419, 420, 490  
 MCL-derived cell line, 189  
 MDR-1, 111  
 Mediastinal B-cell lymphoma, 150  
 Medical history, 345, 363  
 Melphalan, 23, 255, 316, 435, 475, 480, 486, 498  
 Membrane protein, 2, 296  
 Meta-analysis, 4, 305, 369  
 Methotrexate, 34, 42, 342, 485, 492  
 Microarray analysis, 213, 356  
 Microarrays, 12, 86, 173, 179, 185, 196, 197, 198, 199, 213, 356  
 Minimal residual disease, 4, 233, 303, 315, 408, 417, 444  
 Mitoxantrone, 20, 72, 113, 123, 135  
 Molecular cytogenetic analysis, 85  
 Molecular remission, 62, 102, 233, 315  
 Monoclonal antibodies, 65, 70, 145, 185, 261, 266, 281, 319, 362, 412, 413, 445, 504, 508  
 Monoclonal antibody, 70, 145, 261, 319, 362, 445, 508  
 Mononuclear cells, 13, 297, 376  
 Mucositis, 105, 255, 258, 342, 360, 435, 475  
 Multifocal malt lymphoma, 295, 299  
 Multiple myeloma, 118, 154, 190, 249, 298, 357, 428  
 Multiple myeloma, 118, 154, 190, 249, 298, 357, 428, 515  
 Myc, 133, 155, 234  
 Mycosis fungoides, 242, 296, 408  
 Myelodysplastic syndromes, 362  
 Myeloma cells, 357  
 Myelosuppression, 70, 266, 309, 319, 436, 497  
 MZL, 69, 83, 134, 296, 297, 314, 320, 325, 345, 377, 394, 400, 421, 437
- N**
- Neoplastic lymphocytes, 55  
 Neurotoxicity, 34, 36, 279, 437, 457, 466  
 Neutropenia, 16, 22, 63, 66, 67, 69, 70, 71, 74, 105, 107, 109, 110, 112, 122, 125, 126, 135, 137, 144, 152, 153, 157, 158, 160, 164, 212, 235, 236, 237, 239, 249, 261, 264, 266, 283, 288, 298, 299, 304, 306, 308, 311, 318, 331, 341, 342, 343, 350, 354, 355, 359, 436, 437, 438, 439, 460, 463, 477, 488, 497, 507, 508, 513  
 NK cell lymphoma, 100, 243  
 NK cell neoplasms, 58  
 NK cells, 13, 57, 58, 209, 346, 347, 376, 504  
 NK receptors, 209  
 Nodular sclerosis, 59, 150, 203, 282, 370, 411, 499  
 Non-Hodgkin's lymphoma, 1, 6, 20, 25, 49, 60, 66, 68, 69, 70, 73, 88, 89, 90, 91, 92, 93, 95, 97, 99, 101, 105, 111, 113, 125, 126, 137, 138, 140, 142, 144, 152, 153, 154, 155, 156, 157, 159, 168, 170bis, 181, 189, 203, 232, 254, 257, 260, 265, 268, 271, 272, 273, 274, 277, 278, 279, 281, 284, 291, 306, 309, 316, 317, 319, 320, 323, 325, 326,

- 332, 333, 334, 335, 338, 339, 343, 347, 348, 349, 350, 365, 367, 368, 385, 394, 405, 422, 428, 429, 431, 433, 438, 445, 446, 447, 453, 454, 457, 458, 460, 462, 463, 468, 469, 473, 477, 481, 489, 491, 492, 503, 507
- Non-Hodgkin's lymphoma, aggressive, 209, 332, 492
- Novel therapy, 358
- Nucleotide polymorphism, 181
- O**
- Ocular adnexa, 170, 192, 296, 325
- Oesophageal cancer, 93
- Oncogenes, 2, 55, 132, 174, 193, 268, 398
- Outcome prediction, 11
- Outpatient, 42, 125, 160, 236, 238, 249, 457, 512
- Oxaliplatin, 112, 373, 434, 457
- P**
- p21, 154, 183, 192, 194
- p27, 156
- p53, 179, 183, 206, 208, 262, 263, 430
- Pain, 137, 249, 275, 283, 342, 473
- Palliative care, 287
- PARP, 115, 156, 502
- Patient outcome, 46, 502
- Patients, 24, 39, 98, 226, 280, 290, 291, 316, 373, 431, 445, 465, 467, 474, 477, 485, 489, 490
- PCR analysis, 32, 303
- Pegfilgrastim, 110, 112, 288, 290, 418
- Peripheral blood, 12, 13, 15, 32, 38, 40, 42, 57, 62, 64, 67, 68, 114, 172, 201, 214, 297, 303, 316, 336, 346, 374, 377, 383, 388, 406, 408, 413, 432, 435, 441, 458, 474, 477, 478, 479, 495, 511
- Peripheral blood lymphocytes, 201
- Peripheral blood stem cell transplantation, 477
- Peripheral blood stem cells, 435, 479
- Peripheral T-cell lymphoma, 40, 64, 111, 129, 186, 229, 242, 244, 246, 249, 372, 407, 409, 466, 471, 472, 476, 483
- P-glycoprotein, 111
- Pharmacokinetics, 70, 450
- Phase I study, 6, 20, 24, 25, 33, 62, 63, 64, 66, 67, 70, 72, 92, 105, 106, 109, 110, 112, 113, 120, 122, 136, 137, 140, 152, 153, 224, 235, 236, 237, 239, 247, 254, 255, 258, 266, 288, 289, 297, 298, 299, 309, 316, 330, 331, 332, 337, 352, 431, 436, 437, 438, 439, 457, 491, 492, 504, 507, 512, 513
- Phase I/II study, 62, 70, 110, 254, 255, 331
- Phase II study, 6, 20, 24, 25, 33, 63, 64, 66, 67, 72, 92, 105, 106, 109, 110, 112, 113, 120, 136, 137, 140, 152, 153, 224, 235, 236, 237, 239, 247, 255, 258, 288, 289, 297, 298, 299, 309, 316, 330, 331, 332, 431, 436, 437, 438, 439, 457, 491, 492, 512, 513
- Phase III study, 20, 24, 25, 63, 66, 72, 92, 106, 136, 247, 332, 513
- Platelet count, 42, 114, 116, 122, 237, 256, 288, 333, 476
- Platelet transfusion, 164, 477
- PMBL, 146, 147, 149, 150, 174, 274, 338
- Point mutation, 93
- Polymerase chain reaction, 9, 15, 31, 32, 56, 57, 59, 79, 84, 94, 95, 96, 115, 137, 154, 159, 181, 183, 184, 185, 186, 187, 196, 198, 199, 201, 208, 211, 212, 214, 233, 234, 268, 296, 297, 303, 312, 315, 374, 379, 406, 408, 440, 444, 471, 472, 483, 484, 485, 495
- Poor outcome, 15, 49, 71, 81, 194, 239, 263, 340, 427, 432, 441
- Population-based, 9, 231, 321, 337, 447
- Positron emission tomography, 26, 28, 43, 44, 45, 46, 47, 48, 52, 53, 110, 132, 139, 140, 145, 147, 148, 149, 150, 162, 163, 164, 172, 206, 215, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 236, 248, 255, 256, 272, 273, 275, 284, 286, 300, 330, 413, 414, 415, 417, 418, 419, 422, 464, 483, 494, 500
- Pralatrexate, 360, 361
- Predictive factors, 295
- Prednisolone, 20, 195, 418, 456, 488
- Prednisone, 30, 53, 72, 73, 105, 275, 280, 328, 337, 341, 343, 361, 467
- Pregnancy, 166, 323
- Primary central nervous system lymphoma, 34, 259, 463
- Primary follicular lymphoma, 352
- Primary mediastinal B-cell lymphoma, 174, 333, 338
- Primary mediastinal large B-cell lymphoma, 148, 277
- Prognostic factors, 21, 22, 30, 44, 45, 46, 47, 48, 54, 75, 80, 86, 91, 92, 127, 131, 139, 162, 172, 182, 206, 207, 218, 222, 223, 225, 227, 229, 231, 232, 233, 234, 235, 243, 246, 251, 253, 260, 301, 322, 335, 336, 380, 383, 410, 412, 418, 427, 432, 440, 441, 459, 464, 465, 493, 495, 509, 510
- Prognostic index, 48, 102, 110, 322
- Prognostic marker, 12, 172, 194, 227, 230, 321, 373, 380, 389, 392, 405, 440, 510
- Prognostic model, 321, 322, 335, 427, 464
- Prognostic value, 21, 45, 46, 48, 80, 86, 127, 139, 162, 172, 206, 218, 223, 227, 234, 235, 251, 260, 380, 383, 410, 418, 432, 440, 441
- Progression-free survival, 7, 27, 42, 64, 66, 73, 74, 78, 98, 108, 109, 113, 121, 122, 148, 173, 195, 207, 213, 221, 226, 252, 261, 272, 300, 304, 306, 317, 327, 329, 335, 350, 420, 422, 428, 429, 436, 438, 445, 498
- Proliferation, 12, 58, 59, 68, 71, 81, 104, 115, 118, 132, 174, 180, 193, 199, 276, 300, 311, 334, 351, 353, 356, 373, 379, 390, 417, 430, 472, 502, 503
- Proliferation index, 104, 334, 417
- Proliferative index, 199, 220, 300
- Prolonged response, 453
- Prostate cancer, 154
- Proteasome inhibition, 355, 356, 502
- Purine analogs, 319
- Q**
- Quality of life, 3, 5, 19, 36, 166, 292, 453, 492, 496
- R**
- Radioimmunotherapy, 113, 254, 327, 413, 424, 436, 451
- Radiotherapy, 25, 27, 29, 30, 31, 34, 45, 47, 103, 107, 147, 148, 162, 163, 167, 224, 225, 232, 259, 275, 283, 287, 291, 293, 294, 303, 323, 324, 329, 338, 339, 340, 362, 369, 421, 450, 453, 455, 464, 465, 466, 470, 484, 488, 496, 498
- Randomised clinical trials, 7, 447
- Rapamycin, 155, 175, 351
- Ras, 156, 280
- Reduced-intensity conditioning, 98, 246
- Relapsed aggressive lymphoma, 460
- Relapsed lymphoma, 157, 255, 479
- Remission, 16, 18, 23, 28, 31, 32, 33, 36, 40, 45, 61, 62, 84, 91, 97, 101, 103, 105, 108, 109, 125, 126, 138, 164, 211, 215, 225, 228, 233, 237, 248, 259, 272, 275, 281, 287, 299, 304, 305, 309, 311, 314, 327, 331, 341, 343, 346, 407, 411, 412, 418, 420, 432, 436, 439, 444, 448, 454, 455, 456, 459, 460, 461, 467, 469, 473, 477, 479, 480, 483, 484, 486, 490, 491, 495, 498, 499, 515
- Resistant lymphoma, 47, 373
- Response evaluation, 389, 488
- Response rates, 22, 64, 72, 74, 107, 112, 120, 123, 136, 137, 158, 264, 265, 286, 308, 309, 310, 311, 313, 350, 359, 360, 361, 424, 436, 438, 451, 490
- Retrospective analysis, 35, 39, 54, 76, 100, 148, 253, 257, 340, 361, 370, 422, 427, 430, 467, 490
- R-HCVAD, 235, 237
- Risk factors, 9, 37, 92, 100, 148, 220, 260, 269, 283, 284, 285, 291, 292, 363, 427, 455, 456
- Rituxan, 151, 422
- Rituximab, 4, 5, 6, 7, 13, 16, 19, 20, 21, 22, 25, 26, 29, 30, 33, 34, 42, 46, 49, 53, 54, 63, 65, 66, 67, 73, 74, 75, 76, 78, 88, 92, 97, 98, 99, 103, 105, 109, 112, 113, 116, 120, 121, 131, 135, 136, 137, 140, 141, 142, 143, 148, 149, 150, 158, 163, 194, 195, 207, 209, 212, 218, 221, 222, 230, 233, 236, 243, 245, 251, 252, 254, 256, 257, 258, 261, 271, 274, 275, 278, 279, 295, 299, 300, 301, 303, 304, 305, 306, 309, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 324, 325, 326, 328, 329, 330, 335, 337, 339, 340, 342, 343, 348, 349, 362, 385, 389, 400, 413, 414, 420, 422, 424, 426, 427, 428, 429, 433, 434, 435, 436, 437, 445, 447, 448, 450, 456, 457, 458, 460, 461, 463, 466, 467, 478, 479, 483, 485, 486, 491, 498, 505, 506, 507, 512, 513
- Roferon, 136
- Romidepsin, 359, 508
- S**
- Safety profile, 22, 69, 164, 247, 264
- Salvage therapy, 98, 112, 140, 219, 225, 238, 252, 254, 259, 316, 330, 426, 460, 479
- Sarcoma, 8, 27, 376, 473
- sCD30, 270
- Scotland, 291, 324, 511
- Screening, 55, 87, 95, 97, 161, 183, 247, 455, 490
- SCT, 18, 39, 40, 41, 99, 112, 125, 126, 160, 257, 277, 284, 360, 436, 474, 475, 482, 486, 508
- Second malignancies, 283, 294, 315
- Secondary leukemia, 283
- Sequential chemotherapy, 499
- Serum levels, 121, 260, 450
- Signal transduction pathways, 387
- Single cell, 12
- Sinuses, 453
- Skin toxicity, 289, 298
- Small lymphocytic lymphoma, 69, 83, 153, 170bis, 325, 362, 381
- Solid tumors, 27, 156, 172, 201, 468, 473
- Somatic mutation, 60, 154
- Spleen, 96, 104, 178, 186, 229, 276, 325, 336, 413, 427, 448, 492, 493
- Splenectomy, 400
- Splenic marginal zone lymphoma, 268, 400
- Staging, 26, 32, 43, 44, 52, 84, 96, 97, 107, 183, 220, 222, 226, 229, 272, 273, 300, 317, 322, 354, 368, 374, 414, 415, 417, 419, 422, 445, 467, 470, 483
- Stanford V regimen, 107
- STAT3, 82, 131, 353
- Stem cell transplantation, 18, 41, 99, 101, 109, 117, 240, 248, 340, 438, 446, 451, 474, 475, 482, 486
- Stem cells, 3, 18, 33, 41, 62, 73, 98, 99, 101, 108, 109, 112, 117, 125, 127, 145, 160, 164, 212, 219, 221, 232, 240, 248, 252, 283, 284, 288, 315, 316, 339, 340, 355, 360, 362, 436, 438, 446, 451, 457, 463, 466, 474, 475, 476, 477, 478, 480, 481, 482, 486, 496
- Stomach, 192, 295, 336, 367, 405, 413, 419, 484
- Sub-Saharan Africa, 170bis
- Supportive care, 334, 464, 484
- Survival, 3, 4, 5, 7, 10, 11, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 27, 28, 29, 31, 33, 34, 36, 37, 38, 39, 41, 42, 48, 54, 59, 61, 62, 64, 72, 73, 78, 81, 86, 92, 98, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 118, 119, 121, 122, 123, 124, 127, 128, 129, 131, 132, 133, 134, 135, 136, 142, 145, 148, 149, 151, 154, 155, 164, 166, 167, 172, 173, 174, 180, 181, 182, 187, 194, 195, 200, 202, 203, 205, 207, 208, 211, 212, 213, 218, 219, 221, 222, 225, 226, 230, 231, 232, 237, 240, 243, 244, 245, 252, 256, 257, 258, 259, 261, 263, 264, 269, 270, 277, 282, 283, 284, 285, 287, 291, 292, 299, 300, 302, 305, 306, 309, 311, 312, 313, 317, 318, 319, 321, 322, 324, 326, 328, 329, 330, 334, 335, 336, 337, 339, 342, 347, 351, 352, 353, 354, 361, 362, 365, 377, 379, 380, 381, 385, 392, 399, 400, 405, 409, 410, 411, 412, 418, 419, 422, 424, 426, 427, 429, 430, 431, 432, 433, 434, 435, 436, 437, 440, 441, 445, 447, 448, 451, 454, 456, 458, 459, 460, 461, 462, 463, 464, 465,

467, 468, 470, 471, 474, 479, 480, 481, 487, 488, 489, 490, 491, 493, 497, 498, 503  
 Survival advantage, 3, 5, 20, 106  
 Sustained molecular remission, 62  
 Sweden, 284  
 Synergistic activity, 255, 434

**T**

t(11;14)(q13;q32), 133, 356, 406  
 t(11;14) translocation, 179  
 t(11;18), 191, 419, 420  
 t(14;18), 9, 83, 84, 381  
 t(14;18)(q32;q21), 83, 84  
 t(14;18)(q32, 84  
 T-cell, 40, 41, 63, 64, 100, 111, 123, 126, 128, 152, 169, 172, 203, 214, 229, 240, 242, 244, 247, 248, 249, 258, 267, 268, 272, 282, 348, 372, 390, 400, 407, 408, 409, 436, 471, 472, 473, 474, 479, 484, 485, 501  
 T-cell lymphoma, 40, 41, 100, 126, 128, 169, 203, 229, 240, 242, 267, 282, 408, 409, 473, 474, 479  
 Telomere length, 201  
 Temozolomide, 34  
 Testicular lymphoma, 85  
 Thalidomide, 3, 117, 249, 354, 355, 436, 438  
 The Netherlands, 165  
 Thiotepa, 33, 258, 259, 279, 463, 486  
 Thrombocytopenia, 16, 63, 66, 69, 70, 74, 109, 110, 112, 122, 125, 134, 137, 144, 153, 157, 158, 160,

235, 236, 266, 288, 298, 308, 309, 331, 333, 341, 342, 354, 355, 359, 360, 434, 436, 437, 438, 439, 477, 497, 499, 508, 513  
 Thymidine kinase, 121  
 Thyroid MALT lymphoma, 419  
 Time of relapse, 254  
 Tositumomab, 143, 327  
 TP53 mutation, 183, 208  
 Transcription factors, 50, 56, 186, 197, 383  
 Transformed follicular lymphoma, 479  
 Transplantation, 18, 23, 33, 37, 40, 41, 42, 51, 53, 70, 73, 76, 99, 101, 109, 127, 171, 177, 219, 252, 284, 339, 435, 451, 458, 473, 474, 476, 478, 481, 483  
 Transplant-related mortality, 99, 259, 316  
 Treatment choice, 4, 369  
 Treatment modality, 337, 421, 479  
 Treatment outcome, 48, 116, 132, 139, 147, 162, 163, 172, 206, 217, 232, 319, 446, 489, 490  
 Tumor burden, 21, 90, 172, 345, 410  
 Tumor lysis syndrome, 71, 306, 342  
 Tumor markers, 406  
 Tumor necrosis factor-alfa, 62, 118, 270, 350, 377, 387  
 Tumor progression, 279  
 Tumor suppressor genes, 1, 57, 58, 174, 186  
 Tyrosine kinase, 122, 153, 185, 186, 248, 444

**U**

UK, 120, 260, 287, 295, 424, 431, 438, 509

Uric acid, 275, 280

**V**

Vaccination, 61, 62, 141  
 Vascular endothelial growth factor, 204, 377, 472, 510  
 VEBEP regimen, 341  
 VEGF, 204, 377, 472, 510  
 Vinblastine, 418, 488, 497  
 Vinca alkaloids, 495  
 Vincristine, 72, 73, 88, 105, 195, 275, 280, 328, 337, 342, 343, 361, 418, 452, 456, 467, 499  
 Vindesine, 30  
 Vinorelbine, 249, 341, 477  
 Virological response, 138  
 VP16, 88, 89, 418

**W**

WHO classification, 81, 82, 83, 169, 210, 275, 317, 324, 368, 397  
 WM, 114, 115, 116, 134, 153, 190, 319, 502

**Z**

Zevalin, 6, 216, 254, 257